Alerts will be sent to your verified email
Verify Email
SEQUENT
|
Sequent Scientific
|
Guj. Themis Biosyn
|
Orchid Pharma
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Financials
|
|||
|
5 yr Average ROE
|
-0.13 % | 34.65 % | 0.86 % |
|
5yr Avg Net Profit Margin
|
0.03 % | 35.51 % | 0.56 % |
|
Price to Book
|
6.05 | 16.86 | 2.89 |
|
P/E
|
143.64 | 93.91 | 43.03 |
|
5yr Avg Cash Conversion Cycle
|
49.09 Days | -112.39 Days | 52.03 Days |
|
5yr Average Interest Coverage Ratio
|
1.93 | 216.76 | 3.01 |
|
5yr Avg ROCE
|
6.67 % | 45.66 % | 3.08 % |
|
5yr Avg Operating Profit Margin
|
7.74 % | 47.34 % | 11.84 % |
|
5 yr average Debt to Equity
|
0.53 | 0.03 | 0.37 |
|
5yr CAGR Net Profit
|
-25.52 % | 10.07 % | n/a |
|
5yr Average Return on Assets
|
0.05 % | 26.69 % | 1.2 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
52.61 % | 70.86 % | 69.84 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-0.18 % | -4.13 % | -20.12 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
9.79 % | 1.14 % | 16.13 % |
|
Sequent Scientific
|
Guj. Themis Biosyn
|
Orchid Pharma
|
|---|